A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

NCT01284920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Prostate Neoplasms
Castration Resistant Prostate Cancer (CRPC)

Interventions

DRUG: MDV3100

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]